Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - Commercial and partnership strategy

By Claus ThestrupCEO, Sweden
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 17 June 2024 at 10:30 AM.

At this event Julie Waras Brogren will elaborate on the commercial strategy for Orviglance and what investors should expect in terms of partnerships.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. Ascelia Pharma develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 6/6-2024 12.34.

Recent videos

GreenMobility: What is the investment case in driverless cars
05.12.2025 klo 09.00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
04.12.2025 klo 14.00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
04.12.2025 klo 12.32 GreenMobility
Systemair, Audiocast, Q2'25/26
04.12.2025 klo 10.00 Systemair
Hafnia – Presentation of the quarterly report for Q3 2025
02.12.2025 klo 12.00 Hafnia
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.